Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.56 |
| ▸ | CES1 | P23141 | 5/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817443 | 0.91 | PTGS2 (0.57) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL814927 | 0.90 | CES2 (0.52) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL815843 | 0.89 | CES2 (0.56) | CES2CES1ESR1PTGS2LMNA | |
| SCHEMBL5390647 | 0.88 | CES2 (0.50) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL1093948 | 0.87 | NR4A2 (0.55) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL816937 | 0.87 | CES2 (0.58) | CES2CES1PTGS2L3MBTL1LMNA | |
| SCHEMBL6318579 | 0.86 | HSD17B3 (0.46) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL815720 | 0.85 | PTGS2 (0.61) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL8994830 | 0.84 | CES2 (0.47) | CES2CES1ESR1PTGS2L3MBTL1 | |
| SCHEMBL155800 | 0.84 | TDP1 (0.55) | CES2CES1PTGS2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008029278-A2 | CONJUGATES OF ANTITHROMBIN BINDING OLIGOSACCHARIDE DERIVATIVES AND THERAPEUTIC PROTEINS | ENDOTIS PHARMA S.A. (FR) | 2008-03-13 | — | — | WO | claimed |
| EP-1886696-A1 | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins | Endotis Pharma (FR) | 2008-02-13 | — | — | EP | claimed |
| WO-2007135417-A1 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-11-29 | — | — | WO | claimed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | claimed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | claimed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-11931415-B2 | Ophthalmic compositions | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-03-19 | — | — | US | disclosed |
| EP-3496760-B1 | OPHTHALMIC COMPOSITIONS | UNIV LIVERPOOL (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | disclosed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021072473-A1 | ANTIMICROBIALS AS FEED PRESERVATIVES | IRP Health Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
| US-5192799-A | Coumaran group containing amine compounds and their acid addition salts and quaternary ammonium salts and the use thereof as anti arrhythmic agents and as psychotropic agents | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0424525-A1 | NOVEL AMINES AND THEIR USE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| CN-1043319-A | New amine and uses thereof | MITSUI PHARMACEUTICALS (JP) | 1990-06-27 | — | — | CN | disclosed |
| US-4133830-A | RECYCLING BY-PRODUCTS TO SUCCESSIVE RUNS TO IMPROVE YIELD | STAUFFER CHEMICAL COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4130583-A | AUTOGENOUS PRESSURE | STAUFFER CHEMICAL COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | CES2 3314/4885CES1 1629/4885ESR1 4380/4885 |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CES2 4281/4885CES1 4486/4885ESR1 1108/4885 |
| US-11931415-B2 | Ophthalmic compositions | CRYAB, CRYAA, PDE6D | CES2 2565/4885CES1 2344/4885ESR1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.